Leading dopamine agonists will continue to dominate Parkinson's market

19 August 2012

The leading dopamine agonists, pramipexole (Boehringer Ingelheim’s Mirapex/Mirapexin/Sifrol/BI-Sifrol, generics; Mirapex ER/Mirapexin ER/Sifrol Retard/Mirapex LA) and ropinirole (GlaxoSmithKline’s Requip, generics; GlaxoSmithKline/SkyePharma’s Requip XL/LP/RP/Modutab/Prolib, generics), will continue to garner the most substantial sales among therapies used to treat Parkinson’s disease, according to health care advisory firm Decision Resources.

Additionally, the recent re-entry of UCB’s Neupro/Leganto (rotigotine transdermal system) to the US market (The Pharma Letter July 16), its expanding use in Europe and its forecasted launch in Japan will likewise make it one of the top-selling Parkinson’s disease therapies, owing to its once-daily dosing, convenient transdermal delivery, and premium pricing.

Flat sales to 2021 at just $2.5 billion in major markets

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK